Making clear its ambitions in the inflammatory disease space, Gilead Sciences has formed a global partnership with Belgian biotech Galapagos for the development and commercialisation of the Phase III-ready JAK1 (Janus kinase 1) inhibitor filgotinib, committing US$725 M upfront in cash and equity. The deal comes less than 3 months after AbbVie abandoned its collaboration with Galapagos for the drug candidate, instead choosing to advance its internal JAK1 inhibitor ABT-494.